Course Overview: Cardiovascular PET: Moving into F-18 Myocardial Perfusion Imaging – Insights from Experts-F-18 Flurpiridaz: What Do the Data Show?

Video Transcription

Video Summary

Dr. Gary Hiller and Dr. Panethia Sharon Thedaoui discuss the Phase III studies on F18 flirperidase, specifically focusing on the results in obese patients. They found that flirperidase PET provided higher image quality, interpretive certainty, and diagnostic accuracy compared to conventional SPECT myocardial perfusion imaging in patients with a BMI of at least 30. Surprisingly, the sensitivity and specificity in obese patients were the same as those in non-obese patients, which is a significant finding. The higher energy and extraction fraction of fluorperidase, along with its higher contrast resolution, contribute to its ability to provide excellent imaging in larger individuals. The panel sees great potential for fluorperidase in the field of nuclear cardiology, as it offers better image quality, higher diagnostic accuracy, and has the advantage of being unit-dosed, making it more accessible and flexible for various practices. This could potentially democratize PET imaging and expand its use to smaller and more remote healthcare facilities. Overall, fluorperidase brings advancements in patient care and management for those with suspected or known CAD and microvascular dysfunction. The positive results seen in the phase III trials suggest that even legacy PET cameras can provide high-quality images with fluorperidase. There is also potential for its application in special populations such as women and diabetic patients, bringing further benefits to patient care.

Asset Caption

Expert Insights by speaker Panithaya Chareonthaitawee, MD

Keywords

F18 flirperidase

Phase III studies

obese patients

PET imaging

nuclear cardiology